Ei­sai slash­es Leqem­bi sales fore­cast by al­most $100M

Ei­sai has slashed Leqem­bi’s sales fore­cast by 25% this year, low­er­ing the ceil­ing for one of the in­dus­try’s most close­ly-watched drugs.

The com­pa­ny now ex­pects …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER